Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Net Cash Flow came in at $82.1 million in Q1 2026, up 76641.12% YoY from N/an in Q1 2025, and up 965.44% on a QoQ basis from -$9.5 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Net Cash Flow data on file, last reported at $82.1 million in Q1 2026.
- Quarterly Net Cash Flow rose 76641.12% year-over-year to $82.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.8 million (up 214.67% YoY) and the FY2025 annual result came in at -$16.3 million, down 213.34% from the prior year.
- Net Cash Flow grew to $82.1 million in Q1 2026, from -$9.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $82.1 million in Q1 2026 to a low of -$149.5 million in Q1 2023.
- A 5-year average of -$19.7 million and a median of -$5.8 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow sank 665.62% — and 2026, when it surged 76641.12%.
- Tracing BCRX's Net Cash Flow over 5 years: stood at $57.6 million in 2022, then tumbled by 170.47% to -$40.6 million in 2023, then soared by 121.11% to $8.6 million in 2024, then slumped by 210.8% to -$9.5 million in 2025, then surged by 965.44% to $82.1 million in 2026.
- The last three Net Cash Flow figures came in at $82.1 million (Q1 2026), -$9.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | -16.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.96 Mn |
| Jun 30, 2026 | -16.96 Mn |
| Mar 31, 2026 | 82.11 Mn |
| Mar 31, 2026 | 82.11 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Dec 31, 2025 | -9.49 Mn |
| Sep 30, 2025 | -3.62 Mn |
| Sep 30, 2025 | -3.62 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Jun 30, 2025 | -3.26 Mn |
| Mar 31, 2025 | 107,000.00 |
| Mar 31, 2025 | 107,000.00 |
| Dec 31, 2024 | 8.56 Mn |
| Dec 31, 2024 | 8.56 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Jun 30, 2024 | -5.78 Mn |
| Jun 30, 2024 | -5.78 Mn |
| Mar 31, 2024 | -25.98 Mn |
| Mar 31, 2024 | -25.98 Mn |